✦ LIBER ✦

Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

✍ Scribed by Andersen, Kenneth Geving; Jensen, Maj-Britt; Kehlet, Henrik; Gärtner, Rune; Eckhoff, Lise; Kroman, Niels

Book ID: 121366977
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 115 KB
Volume: 51
Category: Article
ISSN: 0284-186X
DOI: 10.3109/0284186X.2012.692884

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

356 Persistent Pain, Sensory Disturbance

356 Persistent Pain, Sensory Disturbances and Functional Impairment After Adjuvant Chemotherapy for Breast Cancer-Cyclophosphamide, Epirubicin and Fluoruracil Compared with Docetaxel + Epirubicin and Cyclophosphamide

✍ K. Geving Andersen; M.B. Jensen; H. Kehlet; R. Gartner; L. Eckhoff; N. Kroman 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Persistent pain, sensory disturbances an

Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer

✍ Kenneth Geving Andersen; Maj-Britt Jensen; Henrik Kehlet; Rune Gärtner; Lise Eck 📂 Article 📅 2012 🏛 Walter de Gruyter GmbH 🌐 English ⚖ 54 KB

Randomized trial of cyclophosphamide, ep

Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan

✍ Morihiko Kimura; Takeshi Tominaga; Yuichi Takatsuka; Masakazu Toi; Rikiya Abe; H 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 224 KB

435 PUBLICATION Comparison of epirubicin

435 PUBLICATION Comparison of epirubicin and vinorelbine with cyclophosphamide, epirubicin, and fluorouracil as neoadjuvant chemotherapy for operable breast cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Phase I trial of adjuvant chemotherapy w

Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer

✍ Stephen E. Jones; Robert G. Mennel; George N. Peters; Mary Alice Westrick; Barry 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 263 KB

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients w

Risk of venous thromboembolism in patien

Risk of venous thromboembolism in patients receiving adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide for early breast cancer

✍ Julia HOY; Teresa NEEMAN; Robin STUART-HARRIS; Alison DAVIS 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB